LXRX
Price
$0.45
Change
+$0.01 (+2.27%)
Updated
Apr 4, 03:46 PM (EDT)
Capitalization
160.21M
27 days until earnings call
PLX
Price
$2.42
Change
-$0.19 (-7.31%)
Updated
Apr 4, 02:49 PM (EDT)
Capitalization
202.88M
35 days until earnings call
Ad is loading...

LXRX vs PLX

Header iconLXRX vs PLX Comparison
Open Charts LXRX vs PLXBanner chart's image
Lexicon Pharmaceuticals
Price$0.45
Change+$0.01 (+2.27%)
Volume$100
Capitalization160.21M
Protalix BioTherapeutics
Price$2.42
Change-$0.19 (-7.31%)
Volume$100
Capitalization202.88M
LXRX vs PLX Comparison Chart
Loading...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LXRX vs. PLX commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXRX is a Hold and PLX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (LXRX: $0.44 vs. PLX: $2.60)
Brand notoriety: LXRX and PLX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXRX: 55% vs. PLX: 68%
Market capitalization -- LXRX: $160.21M vs. PLX: $202.88M
LXRX [@Biotechnology] is valued at $160.21M. PLX’s [@Biotechnology] market capitalization is $202.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXRX’s FA Score shows that 1 FA rating(s) are green whilePLX’s FA Score has 1 green FA rating(s).

  • LXRX’s FA Score: 1 green, 4 red.
  • PLX’s FA Score: 1 green, 4 red.
According to our system of comparison, PLX is a better buy in the long-term than LXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXRX’s TA Score shows that 5 TA indicator(s) are bullish while PLX’s TA Score has 6 bullish TA indicator(s).

  • LXRX’s TA Score: 5 bullish, 2 bearish.
  • PLX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, LXRX is a better buy in the short-term than PLX.

Price Growth

LXRX (@Biotechnology) experienced а +27.50% price change this week, while PLX (@Biotechnology) price change was +0.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.30%. For the same industry, the average monthly price growth was -17.15%, and the average quarterly price growth was -18.93%.

Reported Earning Dates

LXRX is expected to report earnings on May 01, 2025.

PLX is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (-11.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PLX($203M) has a higher market cap than LXRX($160M). PLX YTD gains are higher at: 38.298 vs. LXRX (-39.986). PLX has higher annual earnings (EBITDA): -6.48M vs. LXRX (-184.29M). LXRX has more cash in the bank: 238M vs. PLX (27.4M). PLX has less debt than LXRX: PLX (5.68M) vs LXRX (108M). PLX has higher revenues than LXRX: PLX (45.7M) vs LXRX (31.1M).
LXRXPLXLXRX / PLX
Capitalization160M203M79%
EBITDA-184.29M-6.48M2,846%
Gain YTD-39.98638.298-104%
P/E RatioN/A64.75-
Revenue31.1M45.7M68%
Total Cash238M27.4M869%
Total Debt108M5.68M1,900%
FUNDAMENTALS RATINGS
LXRX vs PLX: Fundamental Ratings
LXRX
PLX
OUTLOOK RATING
1..100
2881
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
80
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9996
PRICE GROWTH RATING
1..100
5435
P/E GROWTH RATING
1..100
172
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LXRX's Valuation (57) in the Biotechnology industry is in the same range as PLX (80) in the Servicestothe Health Industry industry. This means that LXRX’s stock grew similarly to PLX’s over the last 12 months.

LXRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PLX (100) in the Servicestothe Health Industry industry. This means that LXRX’s stock grew similarly to PLX’s over the last 12 months.

PLX's SMR Rating (96) in the Servicestothe Health Industry industry is in the same range as LXRX (99) in the Biotechnology industry. This means that PLX’s stock grew similarly to LXRX’s over the last 12 months.

PLX's Price Growth Rating (35) in the Servicestothe Health Industry industry is in the same range as LXRX (54) in the Biotechnology industry. This means that PLX’s stock grew similarly to LXRX’s over the last 12 months.

PLX's P/E Growth Rating (2) in the Servicestothe Health Industry industry is in the same range as LXRX (17) in the Biotechnology industry. This means that PLX’s stock grew similarly to LXRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LXRXPLX
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
N/A
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HGOIX59.35N/A
N/A
Hartford Growth Opportunities I
RYMMX55.68N/A
N/A
Rydex S&P MidCap 400 Pure Value C
FGFLX39.14N/A
N/A
Federated Hermes Intl Leaders IS
MPLAX13.47N/A
N/A
Praxis International Index A
LGCWX16.60N/A
N/A
Lord Abbett Global Equity R6

PLX and

Correlation & Price change

A.I.dvisor tells us that PLX and ZNTL have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PLX and ZNTL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PLX
1D Price
Change %
PLX100%
+0.39%
ZNTL - PLX
31%
Poorly correlated
-7.55%
CPRX - PLX
31%
Poorly correlated
-1.43%
SNDX - PLX
31%
Poorly correlated
-3.93%
LXRX - PLX
31%
Poorly correlated
-11.91%
MLTX - PLX
30%
Poorly correlated
+0.03%
More